Literature DB >> 9818169

Dystroglycan in development and disease.

M Durbeej1, M D Henry, K P Campbell.   

Abstract

Our understanding of the structure and function of dystroglycan, a cell surface laminin/agrin receptor, has increased dramatically over the past two years. Structural studies, analysis of its binding partners, and targeted gene disruption have all contributed to the elucidation of the biological role of dystroglycan in development and disease. It is now apparent that dystroglycan plays a critical role in the pathogenesis of several muscular dystrophies and serves as a receptor for a human pathogen as well as being involved in early development, organ morphogenesis, and synaptogenesis.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9818169     DOI： 10.1016/s0955-0674(98)80034-3

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN： 0955-0674            Impact factor:   8.382


  27 in total

Review 1.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

2.  The development of the myotendinous junction. A review.

Authors:  Benjamin Charvet; Florence Ruggiero; Dominique Le Guellec
Journal:  Muscles Ligaments Tendons J       Date:  2012-09-10

3.  Deletion of astroglial connexins weakens the blood-brain barrier.

Authors:  Pascal Ezan; Pascal André; Salvatore Cisternino; Bruno Saubaméa; Anne-Cécile Boulay; Suzette Doutremer; Marie-Annick Thomas; Nicole Quenech'du; Christian Giaume; Martine Cohen-Salmon
Journal:  J Cereb Blood Flow Metab       Date:  2012-04-04       Impact factor: 6.200

4.  Golgi phosphoprotein 3 mediates the Golgi localization and function of protein O-linked mannose β-1,2-N-acetlyglucosaminyltransferase 1.

Authors:  Natasha A Pereira; Helen X Pu; Hazel Goh; Zhiwei Song
Journal:  J Biol Chem       Date:  2014-04-14       Impact factor: 5.157

5.  Glycoproteomic characterization of recombinant mouse α-dystroglycan.

Authors:  Rebecca Harrison; Paul G Hitchen; Maria Panico; Howard R Morris; David Mekhaiel; Richard J Pleass; Anne Dell; Jane E Hewitt; Stuart M Haslam
Journal:  Glycobiology       Date:  2012-01-11       Impact factor: 4.313

6.  Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan.

Authors:  M Brockington; D J Blake; P Prandini; S C Brown; S Torelli; M A Benson; C P Ponting; B Estournet; N B Romero; E Mercuri; T Voit; C A Sewry; P Guicheney; F Muntoni
Journal:  Am J Hum Genet       Date:  2001-10-08       Impact factor: 11.025

7.  Proliferative, structural and molecular features of the Mdx mouse prostate.

Authors:  Leslie C Pinto; Wagner J Fávaro; Valéria H A Cagnon
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

8.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

9.  Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan.

Authors:  Elizabeth Stevens; Keren J Carss; Sebahattin Cirak; A Reghan Foley; Silvia Torelli; Tobias Willer; Dimira E Tambunan; Shu Yau; Lina Brodd; Caroline A Sewry; Lucy Feng; Goknur Haliloglu; Diclehan Orhan; William B Dobyns; Gregory M Enns; Melanie Manning; Amanda Krause; Mustafa A Salih; Christopher A Walsh; Matthew Hurles; Kevin P Campbell; M Chiara Manzini; Derek Stemple; Yung-Yao Lin; Francesco Muntoni
Journal:  Am J Hum Genet       Date:  2013-02-28       Impact factor: 11.025

10.  LRP4 is critical for neuromuscular junction maintenance.

Authors:  Arnab Barik; Yisheng Lu; Anupama Sathyamurthy; Andrew Bowman; Chengyong Shen; Lei Li; Wen-cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2014-10-15       Impact factor: 6.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.